Ondansetron Morningside Healthcare

Ondansetron, the active ingredient in Ondansetron Morningside Healthcare, is a 5‑HT3 receptor antagonist presented as an injection for intramuscular and intravenous use. It prevents nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings.

GNH USA supplies Ondansetron Morningside Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used to control emesis in several clinical situations.

- Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: prevents onset of nausea during and after treatment. - Postoperative nausea and vomiting: lowers the frequency of nausea and vomiting after surgical procedures.

Ondansetron may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Injection site pain: local discomfort after administration. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents. - Cardiac arrhythmia: irregular heartbeat, especially in patients with pre‑existing heart disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Ondansetron, clinicians should consider several safety measures.

- Cardiac assessment: evaluate QT interval and correct electrolyte imbalances. - Hepatic function: adjust use in patients with severe liver impairment. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension. - Other QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias. - Serotonergic agents (SSRIs, MAO inhibitors, tramadol): risk of serotonin syndrome. - Carbamazepine: reduces ondansetron plasma concentrations. - Ritonavir: may increase ondansetron levels.

Moderate Interactions (Monitor Closely): - Anticholinergics: may exacerbate constipation. - Glucocorticoids: potential additive effect on QT prolongation. - Anesthetic agents (e.g., propofol): may enhance hypotensive effects.